Holen Sie sich die Stockscreener-App
10.88
0.74%
0.08
Handel nachbörslich:
10.87
-0.01
-0.09%
Schlusskurs vom Vortag:
$10.80
Offen:
$10.82
24-Stunden-Volumen:
183.48K
Relative Volume:
0.81
Marktkapitalisierung:
$415.83M
Einnahmen:
$239.40M
Nettoeinkommen (Verlust:
$104.44M
KGV:
3.6757
EPS:
2.96
Netto-Cashflow:
$-18.50M
1W Leistung:
+2.64%
1M Leistung:
+4.02%
6M Leistung:
+104.51%
1J Leistung:
-13.86%
1-Tages-Spanne:
$10.55
$11.16
1-Wochen-Bereich:
$10.18
$11.41
52-Wochen-Spanne:
$4.93
$13.82
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Firmenname
Entrada Therapeutics Inc
Sektor
Branche
Telefon
857-305-1825
Adresse
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
10.88 | 412.77M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 12.04B | 3.95B | 3.34B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-11 | Eingeleitet | Guggenheim | Buy |
| 2026-01-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2023-04-03 | Eingeleitet | H.C. Wainwright | Buy |
Entrada Therapeutics Inc Aktie (TRDA) Neueste Nachrichten
What analysts say about Entrada Therapeutics Inc. stockWeekly Trade Summary & AI Enhanced Trading Alerts - mfd.ru
Why analysts remain bullish on Entrada Therapeutics Inc. stockBear Alert & Reliable Price Breakout Alerts - mfd.ru
Will Entrada Therapeutics Inc. stock gain from lower inflationJuly 2025 Patterns & Long-Term Capital Growth Ideas - mfd.ru
Entrada Therapeutics (NASDAQ:TRDA) Raised to Strong-Buy at Guggenheim - MarketBeat
Does Entrada Therapeutics (NASDAQ:TRDA) Impact Nasdaq Futures In Biotechnology - Kalkine Media
Published on: 2026-02-13 04:19:34 - mfd.ru
Will Entrada Therapeutics Inc. benefit from rising consumer demandMarket Risk Analysis & High Conviction Buy Zone Alerts - mfd.ru
Can Entrada Therapeutics Inc. outperform under higher oil pricesEarnings Growth Summary & Low Risk Entry Point Tips - mfd.ru
This Olema Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Update Recap: How does Entrada Therapeutics Inc compare to its peersGap Down & High Conviction Trade Alerts - baoquankhu1.vn
Can Entrada Therapeutics Inc maintain sales growthJuly 2025 Outlook & Fast Moving Stock Trade Plans - baoquankhu1.vn
Technical Reactions to TRDA Trends in Macro Strategies - Stock Traders Daily
Entrada Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Entrada CEO Dipal Doshi to join biotech investor talks in New York, Boston - stocktitan.net
Aug Opening: Is STERIS plc stock a good pick for beginnersDollar Strength & Verified High Yield Trade Plans - baoquankhu1.vn
Stock Report: What are the risks of holding Entrada Therapeutics IncQuarterly Performance Summary & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Entrada Therapeutics (NASDAQ:TRDA) Coverage Initiated by Analysts at Oppenheimer - MarketBeat
Aug Shorts: Is Entrada Therapeutics Inc benefiting from innovation trendsRate Hike & Daily Volume Surge Signals - baoquankhu1.vn
Update Recap: Can Entrada Therapeutics Inc outperform under higher oil prices - baoquankhu1.vn
US Market Recap: How volatile is MOGB stockEarnings Summary Report & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Trading the Move, Not the Narrative: (TRDA) Edition - Stock Traders Daily
What insider trading reveals about Entrada Therapeutics Inc. stock2025 Momentum Check & AI Forecasted Stock Moves - bollywoodhelpline.com
Will Entrada Therapeutics Inc outperform the market in YEARTrade Volume Report & Fast Gain Stock Tips - baoquankhu1.vn
Signal Recap: Is Eastman Chemical Company stock a buy or sell2025 Growth vs Value & Technical Confirmation Alerts - baoquankhu1.vn
Quarterly Earnings: Can Onconetix Inc weather a recession2025 Winners & Losers & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
(TRDA) Volatility Zones as Tactical Triggers - Stock Traders Daily
Smart Money: Is Entrada Therapeutics Inc part of any major index2025 Support & Resistance & Safe Capital Investment Plans - baoquankhu1.vn
Entrada Therapeutics: Advancing DMD and DM1 Pipeline with Emerging Ophthalmology Assets Supports Buy Rating and $20 Target - TipRanks
Entrada Therapeutics (NASDAQ:TRDA) Stock Price Down 4.8%Should You Sell? - MarketBeat
Entrada updates progress in preclinical pipeline - BioWorld MedTech
Entrada Therapeutics reports progress across development portfolio - Yahoo Finance
Analyst Calls: Is Entrada Therapeutics Inc. stock safe for conservative investorsQuarterly Investment Review & AI Driven Stock Reports - Улправда
Is Entrada Therapeutics Inc. stock vulnerable to regulatory risks2025 Market Trends & Accurate Technical Buy Alerts - Улправда
Entrada Therapeutics Highlights Progress Across Its Portfolio of Rna-Based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases - marketscreener.com
Entrada Therapeutics highlights RNA pipeline progress and outlook - TipRanks
Entrada reports progress on DMD treatments, shares clinical timeline By Investing.com - Investing.com Australia
Entrada Therapeutics Advances Clinical Pipeline and Reports Progress Amid Upcoming Data Releases and New Ocular Candidate Selection - Quiver Quantitative
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases - The Manila Times
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases - GlobeNewswire Inc.
Entrada Therapeutics Reports Increased Losses Amid R&D Expansion - MSN
Price-Driven Insight from (TRDA) for Rule-Based Strategy - Stock Traders Daily
Azenta elects Entrada CEO to Board of Directors - MSN
Vesuvius India Limited Moves Into Overbought Range Analysts CautiousSell Signals and Alerts & Double Or Triple Wealth - bollywoodhelpline.com
Entrada Therapeutics Inc (TRDA) Stock News & Articles - 24/7 Wall St.
AVP Infracon Limited Breaks Below Key Support LevelGlobal Trade Effects & Affordable Trading Strategies - Bollywood Helpline
Analyst Downgrade: Will Entrada Therapeutics Inc stock return to pre crisis levels2025 Market Overview & Verified Entry Point Detection - Bộ Nội Vụ
Tubes Limited Inches Toward Key Resistance — Will It BreakRisk Adjusted Returns & Low Risk Trading Ideas - Bollywood Helpline
Beeyu Overseas Limited Included in Top Momentum ScanVolume Profile Analysis & Big Data Market Reports - Bollywood Helpline
Option Seller’s Risk Unlimited (in theory)REITs Market Trends & Big Gains Small Capital - bollywoodhelpline.com
Entrada Therapeutics, Inc.Common Stock (NQ: TRDA - FinancialContent
Finanzdaten der Entrada Therapeutics Inc-Aktie (TRDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):